Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
Guardado en:
| Publicado en: | Nature Medicine vol. 29, no. 6 (Jun 2023), p. 1468 |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , , , , |
| Publicado: |
Nature Publishing Group
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Resumen: | Rett syndrome is a rare, genetic neurodevelopmental disorder. Trofinetide is a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome. In this phase 3 study (<ext-link xlink:href="https://clinicaltrials.gov" ext-link-type="url">https://clinicaltrials.gov</ext-link> identifier <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04181723?term=NCT04181723&draw=2&rank=1" ext-link-type="url">NCT04181723</ext-link>), females with Rett syndrome received twice-daily oral trofinetide (n = 93) or placebo (n = 94) for 12 weeks. For the coprimary efficacy endpoints, least squares mean (LSM) change from baseline to week 12 in the Rett Syndrome Behaviour Questionnaire for trofinetide versus placebo was −4.9 versus −1.7 (P = 0.0175; Cohen’s d effect size, 0.37), and LSM Clinical Global Impression–Improvement at week 12 was 3.5 versus 3.8 (P = 0.0030; effect size, 0.47). For the key secondary efficacy endpoint, LSM change from baseline to week 12 in the Communication and Symbolic Behavior Scales Developmental Profile Infant–Toddler Checklist Social Composite score was −0.1 versus −1.1 (P = 0.0064; effect size, 0.43). Common treatment-emergent adverse events included diarrhea (80.6% for trofinetide versus 19.1% for placebo), which was mostly mild to moderate in severity. Significant improvement for trofinetide compared with placebo was observed for the coprimary efficacy endpoints, suggesting that trofinetide provides benefit in treating the core symptoms of Rett syndrome.Results from the LAVENDER phase 3 study demonstrate that trofinetide, a synthetic analog of glycine–proline–glutamate, provides significant therapeutic benefits in the core symptoms of Rett syndrome |
|---|---|
| ISSN: | 1078-8956 1546-170X |
| DOI: | 10.1038/s41591-023-02398-1 |
| Fuente: | Science Database |